Post-surgical shunt hepatopulmonary syndrome in a case of non-cirrhotic portal hypertension: lack of efficacy of shunt reversal

• Published in: European journal of gastroenterology & hepatology Vol. 11; no. 12; p. 1425
• Main Authors: Hannam, P D, Sandokji, A K, Machan, L S, Erb, S R, Champion, P, Buczkowski, A K, Scudamore, C H, Steinbrecher, U P, Chung, S W, Weiss, A A, Yoshida, E M
• Format: Journal Article
• Language: English
• Published: England 01.12.1999
• Subjects: Adult; Hepatopulmonary Syndrome - etiology; Hepatopulmonary Syndrome - surgery; Humans; Hypertension, Portal - complications; Hypertension, Portal - surgery; Liver Diseases - complications; Liver Transplantation; Male; Portasystemic Shunt, Surgical; Postoperative Complications - etiology
• ISSN: 0954-691X
• DOI: 10.1097/00042737-199912000-00015

Hepatopulmonary syndrome, a consequence of significant liver disease and portal hypertension, is thought to be secondary to the effects of vasoactive substances, normally inactivated in the liver, on the pulmonary vasculature. We report a patient with preserved hepatic function who underwent a decompressive surgical porto-systemic shunt for non-cirrhotic portal hypertension. This patient developed hepatopulmonary syndrome with dyspnoea and oxygen desaturation 2 years post-surgical shunt. Over the next 7 years, the patient's respiratory function became increasingly impaired although hepatic function remained preserved. Because of the hypothesized role of porto-systemic shunting in the aetiology of this syndrome, the surgical shunt was successfully reversed angiographically. No improvement in dyspnoea or oxygen saturation occurred and liver transplantation was undertaken. Six months post-transplant, the patient has decreased his oxygen requirements and is free of dyspnoea. Our experience supports the causal role of porto-systemic shunting in the pathogenesis of hepatopulmonary syndrome but suggests that merely decreasing the extent of porto-systemic shunting is not beneficial. Liver transplantation remains the only reliable therapeutic modality available to these patients.